To advance in the validation of OPN as a potential biomarker for diagnosing MS at onset, next steps should emphasize the use of ELISA as a uniform methodology to ensure reliable comparisons and allow the definition of sensitivity and specificity for OPN detection. Here, SPP1 is linked to myeloid sarcoma.